{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-281574","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.122925+00:00","generated_at":"2026-06-07T22:28:41.366106+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Acadia Pharma EVP R&D Doug Williamson to depart; search for replacement underway","bullets":["Doug Williamson, MD, EVP Head of R&D, leaving Acadia to pursue other opportunities.","Williamson joined Acadia in January 2023 and will remain during a transitional period.","Company has initiated a search for a replacement EVP of Research and Development.","No financial impact or guidance changes disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-281574","json":"https://secwatch.observer/filing/0001193125-23-281574.json","markdown":"https://secwatch.observer/filing/0001193125-23-281574.md","text":"https://secwatch.observer/filing/0001193125-23-281574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523281574/0001193125-23-281574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523281574/d586090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:28:41.366106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}